Please assess the completion status of the following clinical trial:

Trial Title: Oxytocin Treatment of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meeting DSM-IV criteria for paranoid or undifferentiated schizophrenia for at least 1 year.~* Scoring \> or equal to 4 on the suspiciousness/persecution (paranoia) subscale of the Positive and Negative Symptoms Scale (PANSS), a full PANSS score \> or equal to 60: stability of symptom severity and on the same medication(s) and dose(s) for at least 1 month; low to moderate depressive symptoms.~Exclusion Criteria:~* Low literacy as indicated by an inability to read and understand the consent form.~* Dependence on substances other than tobacco or caffeine.~* Positive urine drug screen for illegal substances or drugs that have not been prescribed.~* Debilitating medical conditions (including AIDS; HIV infection alone will not be grounds for exclusion).~* Major surgery or trauma in the past year will be grounds for exclusion although subjects determined to be recovered and stable may be included at the discretion of the PI.~* Pregnancy, breast-feeding.~* Having given birth in the past 6 months or breast-feeding in the past 3 months.~* Individuals judged unable to learn self-administration of intranasal treatments and/or not sufficiently reliable to do so will be excluded.~* Abnormalities found during medical evaluation will be grounds for exclusion although subjects with laboratory measures barely outside the normal range may be included at the discretion of the Principal Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- intranasal spray with oxytocin (Type: EXPERIMENTAL): Twice daily intranasal oxytocin spray (24 IU, 6 insufflations/dose) for 6 weeks
- intranasal spray without oxytocin (Type: PLACEBO_COMPARATOR): Twice daily intranasal spray without oxytocin (six 0.1 ml insufflations/dose) for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).